Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Neutrolis Inc. is managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are split between 2 distinct examiners and 2 distinct art units. This indicates that each of the 2 pending office actions is being handled by a different examiner in a different specialized group, which prevents the consolidation of prosecution efforts.
NOAKES, SUZANNE MARIE is the busiest examiner, with 1 pending office action. Because there are 2 distinct examiners for 2 pending actions, there is no overlap in the personnel reviewing the company applications. Practitioners must address the specific requirements of two separate art units and two different examiners simultaneously. The presence of 2 pending office actions across 2 distinct art units suggests that the company technical focus is divided between different specialized areas of biotechnology. This distribution requires a strategy that can adapt to the varying examination cultures of different USPTO divisions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NOAKES, SUZANNE MARIE | 1 | 73.4% | +18.3% |
| IANNUZO, NATALIE NMN | 1 | 12.2% | +71.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17193455 | ENGINEERED DNASE ENZYMES AND USE IN THERAPY | IANNUZO, NATALIE NMN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18798042 | ENGINEERED HUMAN EXTRACELLULAR DNASE ENZYMES | NOAKES, SUZANNE MARIE | — |
| 17193455 | ENGINEERED DNASE ENZYMES AND USE IN THERAPY | IANNUZO, NATALIE NMN | — |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18798042 | ENGINEERED HUMAN EXTRACELLULAR DNASE ENZYMES | NOAKES, SUZANNE MARIE | 1656 | §102DP | Non-Final OA | — | Pending | Aug 08, 2024 |
| 17193455 | ENGINEERED DNASE ENZYMES AND USE IN THERAPY | IANNUZO, NATALIE NMN | 1653 | §103 | Final Rejection | — | Pending | Mar 05, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNeutrolis Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Suzanne Marie Noakes has the most, with 1 of Neutrolis Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
